Indegene Limited · NSE:INDGN

Indegene — Investor Presentation (March 2025)

45 slides from Indegene's investor presentation, Mar 26, 2025

Slide 1: Investor Presentation Intimation under Regulation 30
INDGN/SE/2024-25/129 March 26, 2025 BSE Limited, National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers, Exchange Plaza, C-1, Block G, Dalal Street, Bandra Kurla Complex, Bandra (E), Mumbai- 400001, India. Mumbai – 400 051, India. Scrip Code: 544172 Trading symbol: INDGN Dear Sir / Madam
Slide 2: Indegene's Approach to Gen AI
Indegene’s Approach to Gen AI March 2025
Slide 3: Trends in Embedding LLMs into Business Processes
Trends in Embedding LLMs into Business Processes Initial Phase: Intermediate Phase: Current Phase: Prompt Engineering Retrieval-Augmented Generation (RAG) Agents and Multi-Agent Orchestration • Zero-shot, few-shot: Basic interaction • Responses grounded in curated external • Autonomous, reasoning-ca
Slide 4: Our PoV on Building Agentic Business Applications
Our PoV on Building Agentic Business Applications Current Importance of Knowledge Trends Engineering Increasing perspective Codification: Ontologies that AI agents will and taxonomies with manage application logic domain- and business- specific relationships Agentic workflows will drive technology e
Slide 6: SME Workbench: Engineering using DSL
SME Workbench: Engineering using DSL (Domain Specific Language) Revised SDLC with Domain Experts owning GenAI services and Engineering consuming those services © 2025 Indegene. All rights reserved. 5
Slide 7: Cortex
Cortex Designed to scale the adoption of LLM-based verticalized agents across use cases with a pragmatic enterprise-grade approach Knowledge Engineering Led By Domain Experts Business Applications (Use Cases) Built With Agents Safety DB LLMs API Model Domain Context Knowledg Fit-for-Purpose Agents P
Slide 8: Cortex
Cortex Knowledge Engineering Interface (KEI): The KEI allows subject matter experts to codify domain process knowledge into knowledge graphs using a domain expert friendly interface. It facilitates evaluation of the depth and quality of the codified knowledge as well as continuous improvement. These
Slide 9: Cortex Interoperability for IT Application Integration
Cortex Interoperability for IT Application Integration Enterprise System Integration (AWS, Azure, SF, Open AI etc) Client MCP (Model Context Protocol) Domain standards-based API for Knowledg Fit-for-Purpose Agents integration into IT applications e Graphs D s om nt on M a in S e lti i M E Ag -A at u
Slide 10: Executive Summary of Indegene's View
Executive Summary of Indegene’s View Agents and Multi- Successful A platform approach Leveraging modern Agent orchestration transformation of facilitates the shift of agent interoperability bring us closer to business processes fragmented point standards and / or embedding LLMs into through technolo
Slide 11: Thank You!
Thank You! www.indegene.com
Slide 12: Gen AI in Commercial
Gen AI in Commercial March 2025
Slide 13: Gen AI-Powered Agentic Workflows in Commercial
Gen AI-Powered Agentic Workflows in Commercial Agent Driven Content Creation & Experience Delivery & Activation MLR Automation ➢ Contextual and human-like experience in ➢ Accelerating creative, copy, and Digital delivery with immersive channels modular content production Experiences E.g. Digital Ava
Slide 14: Indegene as a Front-Runner in AI-Ideas to Action Report
Indegene as a Front-Runner in its ‘‘AI-Ideas to Action’’ Operationalizing Generative AI in Life Sciences’ Market Report -2025 © 2025 Indegene. All rights reserved. 13
Slide 15: Expanding Focus & Disrupting Value Chains With Gen AI
Expanding Focus & Disrupting Value Chains With Gen AI Shifting Left (Upstream) Current Core Focus Shift Right (Downstream) (Research, Ideation & Concepting) (Content Creation & Production) (Localization, Delivery & Optimization) Brand Strategy & Creative Conceptualization & Offshore MLR & Campaign A
Slide 16: Super Agent – Gen AI Operating System for Commercial
Super Agent – Gen AI Operating System for Commercial Personalization at Scale Becomes the Standard, Not the Aspiration GenAI Instant Content & Experience with Enterprise Content Super Agent Trust & Global Scale Powered by Powered by Cortex 3P (Precision, Personalization, Performance) 3x Variation in
Slide 17: Enabling Value Through Super Agent
Enabling Value Through Super Agent And In Production With Top Pharma Character Generation Image Generation Creative Design & Wireframe Creatives Concepting Agent & Localization & Localization Storyboarding Agent Template Generation Generation Copy/ Content Content Localization & Written Content Cont
Slide 18: Layered Super Agent Architecture
Layered Super Agent Architecture Concepting Content AI Immersive Replicator MLR Agent & Creative Agent Agent Studio Agent Agents Layer Playground Apps CORTEX Element management G2L Claim Mapping Management Business Rules Management Manuscript Rules Management Cortex Metadata Management Clustered Ele
Slide 19: Making it real: Pillars that Power the future
Making it real: Pillars that Power the future 01 02 03 Responsible AI Trust Layer Enablement Pharma Guardrails • FASTER Framework • Explainable AI • Disclosures • Compliance Standards- NIST AI RMF • Logging and Traceability • Label Codifications • Data Privacy Regulations: GDPR, EU AI • Prompt Secur
Slide 20: Transforming Marketer Experience with GenAI
Transforming Marketer Experience with GenAI – Solving Content Scarcity & Personalization Immersive Studio Replicator Agent ❑ Gen AI Avatar Based Videos ❑ Gen AI Concepting and Content Podcasting Creative Translation Localization Personalization Analytics with Camillia M (Concepting Agent) ❑ Gen AI A
Slide 22: Why Indegene Wins
Why Indegene Wins Enterprise-grade Gen AI solutions , purpose-built for Pharma. Trusted by IT, proven with Brand Teams. Fit For Purpose LLM Applications & Agents Research & Content Creative Campaign Strategy Analytics Workflow Localization Experience & Insights Collaboration MOAT Built On Our Propri
Slide 23: Thank You!
Thank You! www.indegene.com
Slide 24: Generative AI Enterprise Medical
Generative AI Enterprise Medical March 2025
Slide 25: Understanding the R&D value chain and EMS's service lines
Understanding the R&D value chain and EMS’s service lines Pre-market data sources Post-market data source Clinical Trials Research Publications Post-marketing safety data RWD Other data stores (E.g. Regulatory correspondence) Research publications Post marketing studies Regulatory Safety Data Analys
Slide 26: The focus of our solutions is aligned to our clients'
Non-Exhaustive The focus of our solutions is aligned to our clients’ Solutions Focus Convert data into regulatory Regulatory Data Analysis Authoring Regulatory Submissions submissions document Product impact Product attributes Regulatory compliant formats E.g Safety & Efficacy E.g Product stability,
Slide 27: Enterprise Medical Services' GenAI solutions
Enterprise Medical Services’ GenAI solutions 1 2 3 Medical Affairs Pharmacovigilance Regulatory Affairs MLR Review Adverse Events Automation Management Medical Content Medical Writing Automation Automation Literature Surveillance © 2025 Indegene. All rights reserved. 26
Slide 28: Our NEXT suite addresses fundamental objectives of life sciences organisations
Our NEXT suite address some fundamental objectives of Lifesciences organisations Speed to Speed to Enhanced Efficiency market submission compliance MLR Review Automation Y Y Y Medical Content Automation Y Y Adverse Events Management Y Y Literature Surveillance Y Y Medical Writing Automation Y Y Y ©
Slide 29: IP stack that significantly differentiates our solutions
Along the way, we have built an IP stack that significantly differentiates our solutions Different technologies/ technical & solution levers, and learnings* Pre- and post- Document parsing and Identification and processing and data Chunking and retrieval extraction models analysis structuring Metada
Slide 30: Great traction with GenAI across the Life Sciences value chain
We’ve had great traction with GenAI across the Life Sciences value chain, but a lot of headroom remains Medical Affairs Safety and Pharmacovigilance Regulatory writing • Lit Search and Screening • Aggregate reporting • Protocol to ICF, PLPS • SRD creation • Literature management • Response to Querie
Slide 33: The Engine Underneath: Indegene's Capabilities at Work
The Engine Underneath: Indegene’s Capabilities at Work Source Integration Patient Cases Line Listings CSRs Web APIs: External websites - e.g., FDA, EMA, Industry newsletters etc. GenAI enabled Transformation Layer Document Pre- and post- Data Stores and Identification Transformation parsing and proc
Slide 34: Horizontal Capabilities Enabling Seamless Adaptation Across Report Types
Horizontal Capabilities Enabling Seamless Adaptation Across Report Types Clinical Study Reports Aggregate Reports Label updates Standard Response Docs Plain Language Summaries Informed Consent Forms © 2025 Indegene. All rights reserved. 33
Slide 35: Contextualizing core capabilities for Aggregate Report sections
Case In Point: Contextualizing core capabilities for Aggregate Report sections to deliver up to 40-60% automation PBRER Sections Effort reduction Core-capabilities (as archetype report) (after QC of Gen. AI output) Introduction | Worldwide marketing auth status | 50-65% • Relevant info. from contrib
Slide 36: Leveraging Gen AI for PSUR Authoring Automation
Leveraging Gen AI for PSUR Authoring Automation Business Need Outcomes delivered • The Client , a global biopharmaceutical company, was looking to reduce the time taken to author its aggregate reports and bring about operational efficiencies in the end-to-end authoring workflow enabling consistency
Slide 38: GenAI led asset generation with human in the loop
GenAI led asset generation with human in the loop User Inputs Source search Content outline Section content Enterprise Data Integration Asset design Publish User led refinement © 2025 Indegene. All rights reserved. 37
Slide 40: GenAI assisted MLR review platform (in production use)
GenAI assisted medical, legal, regulatory (MLR) review platform (in production use) Reg and Industry Code Fact Validation Label Compliance Image Validations Compliance Claims and scientific Asset is checks for reg and Appropriate content Graphs, figures and statements are identified industry code vi
Slide 42: NEXT Adverse Events Management
NEXT Adverse Events Management Indegene proprietary GenAI platform for case processing automation Indegene has delivered >600K live cases via NEXT Adverse Events Management in production Intake Channels Integrate and Process and assess case- leverage Submission Safety DB OR Intake via DB integration
Slide 44: NEXT Literature Surveillance
NEXT Literature Surveillance NEXT Literature Surveillance is envisioned to automate ~70% of literature processing effort Literature Sources Automated/ De-duplication and Entity Extraction and Downstream scheduled searches relevancy based screening downstream reporting Use Pubmed/ Embase NEXT Literat
Slide 45: Thank You!
Thank You! www.indegene.com

Indegene — Investor Presentation (March 2025) on 6ix

Indegene — Investor Presentation (March 2025)

Slide 1: Investor Presentation Intimation under Regulation 30

Slide 2: Indegene's Approach to Gen AI

Slide 3: Trends in Embedding LLMs into Business Processes

Slide 4: Our PoV on Building Agentic Business Applications

Slide 5: True Verticalization Approach

Slide 6: SME Workbench: Engineering using DSL

Slide 7: Cortex

Slide 8: Cortex

Slide 9: Cortex Interoperability for IT Application Integration

Slide 10: Executive Summary of Indegene's View

Slide 11: Thank You!

Slide 12: Gen AI in Commercial

Slide 13: Gen AI-Powered Agentic Workflows in Commercial

Slide 14: Indegene as a Front-Runner in AI-Ideas to Action Report

Slide 15: Expanding Focus & Disrupting Value Chains With Gen AI

Slide 16: Super Agent – Gen AI Operating System for Commercial

Slide 17: Enabling Value Through Super Agent

Slide 18: Layered Super Agent Architecture

Slide 19: Making it real: Pillars that Power the future

Slide 20: Transforming Marketer Experience with GenAI

Slide 21: Demos

Slide 22: Why Indegene Wins

Slide 23: Thank You!

Slide 24: Generative AI Enterprise Medical

Slide 25: Understanding the R&D value chain and EMS's service lines

Slide 26: The focus of our solutions is aligned to our clients'

Slide 27: Enterprise Medical Services' GenAI solutions

Slide 28: Our NEXT suite addresses fundamental objectives of life sciences organisations

Slide 29: IP stack that significantly differentiates our solutions

Slide 30: Great traction with GenAI across the Life Sciences value chain

Slide 31: SME Workbench

Slide 32: NEXT Medical Writing Automation

Slide 33: The Engine Underneath: Indegene's Capabilities at Work

Slide 34: Horizontal Capabilities Enabling Seamless Adaptation Across Report Types

Slide 35: Contextualizing core capabilities for Aggregate Report sections

Slide 36: Leveraging Gen AI for PSUR Authoring Automation

Slide 37: NEXT Medical Content Automation

Slide 38: GenAI led asset generation with human in the loop

Slide 39: NEXT MLR Review Automation

Slide 40: GenAI assisted MLR review platform (in production use)

Slide 41: NEXT Adverse Events Management

Slide 42: NEXT Adverse Events Management

Slide 43: NEXT Literature Surveillance

Slide 44: NEXT Literature Surveillance

Slide 45: Thank You!